Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .


Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Several million euros in funding for systems biologists at DKFZ

No. 09 | 05/03/2012

In February and March of this year, three new research consortia have started work at DKFZ. They are funded by the Federal Ministry of Education and Research (BMBF) as part of its program ”Systems Biology in Cancer Research – CancerSys” and will receive funds amounting to nine million euros over a three-year period. The networks, called LungSys-II, CancerEpiSys and MYC-NET, combine experimental measuring methods with mathematical models with the aim of exploring the complex molecular processes involved in the development of cancer. To this end, DKFZ researchers collaborate closely with researchers at Heidelberg and Ulm University Hospitals and with companies such as Roche.

The latest methods in sequencing make even small genomic and epigenomic alterations in tumor cells visible. Picture: illumina

Studying resistance of cancer cells
In the “MYC-NET” consortium, a team of researchers from DKFZ and Heidelberg University headed by Dr. Frank Westermann, Prof. Dr. Thomas Höfer and Dr. Stefan Pfister is investigating the molecular mechanisms that make cancer cells of pediatric brain tumors resistant to chemotherapy or radiotherapy. In many patients, these treatments cause mutations which help cancer cells to become resistant to therapy. In order to understand how these mutations impact the finely tuned balance between cell death and cell division, the group combines genetic, biochemical, systems-biological and mathematical approaches. In particular, they plan to observe under the microscope, for the first time, how cancer cells respond to chemotherapy in order to characterize the variability of cellular behavior and the selection of therapy-resistant cancer cells at individual cell level.

Packaging also plays a role
How can we treat one of the most frequent types of blood cancer in the Western world, chronic lymphocytic leukemia, more effectively? This question is being explored by scientists in the research network “CancerEpiSys”.

The fact that cancer cells do not behave like normal cells is not only due to alterations in the genetic information as such, but also in its “packaging”. Changes affecting the packaging can lead to the genetic information not being read correctly. As a result, an affected cell may turn off genes that normally prevent carcinogenesis. The research discipline that studies the manifold interactions of “packaging” and genetic information is called epigenetics. “We try to filter out epigenetic connections that are key to the development of and fight against chronic lymphocytic leukemia,” said Dr. Karsten Rippe of the German Cancer Research Center and Dr. Daniel Mertens of the Department of Internal Medicine III of Ulm University Medicine, the coordinators of the new research network. At the same time, the researchers endeavor to find out how anticancer drugs with epigenetic working mechanisms influence these factors.

Optimum treatment of advanced lung cancer
In Germany, lung cancer is the most frequent cause of cancer-related death in men and the third most frequent in women. Most patients are treated by chemotherapy, which often leads to anemia as a side effect. Therefore, patients are frequently treated with a drug called erythropoietin (EPO) alongside chemotherapy; EPO promotes the formation of red blood cells, thus securing oxygen supply. However, in recent years researchers have found receptors for EPO on tumor cells, too, so that the drug, fatally enough, also promotes their growth.

Which effect will ultimately be stronger in a treatment with EPO is determined by a multitude of factors which mutually impact each other. The resulting complexity can best be captured by a systems biology approach, which processes data from experimental research in mathematical models. Scientists in the group of Prof. Dr. Ursula Klingmüller from DKFZ are networking in the “LungSys II” consortium in an effort to use systems biology to make the treatment of lung cancer patients with erythropoietin safer.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS